The Vogel conflict test: Procedural aspects, γ-aminobutyric acid, glutamate and monoamines

European Journal of Pharmacology

Volumn 463, Issue 1-3, 2003, Pages 67-96

  Millan, Mark J ^a   Brocco, Mauricette ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

5 HT1A receptor; Anxiety; Anxiogenic; Anxiolytic; Benzodiazepine; Limbic system; Stress

Indexed keywords

1 (1,4 BENZODIOXAN 5 YL) 4 (2 INDANYL)PIPERAZINE; 1 (4,4 DIPHENYL 3 BUTENYL)GUVACINE; 1 [5 (2 THIENYLMETHOXY) 3 INDOLYL] 2 PROPANAMINE; 2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; 2,3,6,7 TETRAHYDRO 1' METHYL 5 [[2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL) 4 BIPHENYLYL]CARBONYL]SPIRO[FURO[2,3 F]INDOLE 3,4' PIPERIDINE]; 3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 (4 METHYL 1 PIPERAZINYL) 7 TRIFLUOROMETHYLPYRROLO[1,2 A]QUINOXALINE; 4 AMINOBUTYRIC ACID; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; ACETYLENE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ALPHA [1 [2 (1,4 BENZODIOXAN 5 YLOXY)ETHYL] 3 PYRROLIDINYL] 4 FLUOROACETOPHENONE; ALPRAZOLAM; ANXIOLYTIC AGENT; BACLOFEN; BENZODIAZEPINE; BRETAZENIL; CHLORDIAZEPOXIDE; CLORAZEPATE; DIAZEPAM; ELTANOLONE; EXCITATORY AMINO ACID; GLUTAMIC ACID; HORMONE; IMIDAZENIL; LY 326 325; LY 354 740; MONOAMINE; MUSCIMOL; N METHYL BETA CARBOLINE 3 CARBOXAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROPEPTIDE; NEUROPEPTIDE RECEPTOR; NEUROTROPHIN; PICROTOXIN; PROPOFOL; S 32504; SB 215 505; SKF 100 330; SL 651 498; TRIAZOLAM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALERIC ACID; ZOLPIDEM;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; AVERSION; CONDITIONING; CONFLICT; CONTROLLED STUDY; DRINKING BEHAVIOR; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; EMOTION; GABAERGIC SYSTEM; MALE; MONOAMINERGIC SYSTEM; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; RAT; STRESS; WATER DEPRIVATION;

EID: 0037470221     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01275-5     Document Type: Article

References (458)

1. 2 receptor regulation of extracellular GABA levels in the prefrontal cortex. Neuropsychopharmacology. 21:1999;92-96.
2. 3 dopamine receptor gene is associated with hyperactivity in mice. Proc. Natl. Acad. Sci. U. S. A. 93:1996;1945-1949.
3. Adell A., Casanovas J.M., Artigas F. Comparative study in the rat of the actions of different types of stress on the release of 5-HT in raphe nuclei and forebrain areas. Neuropharmacology. 36:1997;735-741.
4. Ågmo A., Pruneda R., Guzman M., Gutiérrez M. GABAergic drugs and conflict behavior in the rat: lack of similarities with the actions of benzodiazepines. Naunyn-Schmiedeberg's Arch. Pharmacol. 344:1991;314-322.
5. Ågmo A., Galvan A., Heredia A., Morales M. Naloxone blocks the antianxiety but not the motor effects of benzodiazepines and pentobarbital: experimental studies and literature review. Psychopharmacology. 120:1995;186-194.
6. Aguilera G., Radadan-Diehl C. Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation. Regul. Peptides. 96:2000;23-29.
7. Ahmed I., Takeshita J. Clonidine: a critical review of its role in the treatment of psychiatric disorders. CNS Drugs. 6:1996;53-70.
8. Amano M., Goto A., Sakai A., Achiha M., Takahashi N., Hara C., Ogawa N. Comparison of the anticonflict effect of buspirone and its major metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in rats. Jpn. J. Pharmacol. 61:1993;311-317.
9. Amin J. A single hydrophobic residue confers barbiturate sensitivity to γ-aminobutyric acid type C receptor. Mol. Pharmacol. 55:1999;411-423.
10. Andrews N., File S.E. Handling history of rats modifies behavioural effects of drugs in the elevated plus-maze test of anxiety. Eur. J. Pharmacol. 235:1993;109-112.
11. 1A receptors in the median raphe nucleus and dorsal hippocampus may mediate anxiolytic and anxiogenic behaviours respectively. Eur. J. Pharmacol. 264:1994;259-264.
12. Apter J.T., Allen L.A. Buspirone: future directions. J. Clin. Psychopharmacol. 19:1999;86-93.
13. Arnsten A.F.T. Catecholamine regulation of the prefrontal cortex. J. Psychopharmacol. 11:1997;151-162.
14. 3 receptor antagonist with anxiolytic properties in animal models. Psychopharmacology. 117:1995;137-148.
15. Aston-Jones G., Rajowski J., Cohen J. Role of locus coeruleus in attention and behavioral flexibility. Biol. Psychiatry. 46:1999;1309-1320.
16. Babar E., Özgünen T., Melik E., Polat S., Akman H. Effects of ketamine on different types of anxiety/fear and related memory in rats with lesions of the median raphe nucleus. Eur. J. Pharmacol. 431:2001;315-320.
17. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 38:1999;1083-1152.
18. 1A drugs in the pigeon. Drug Dev. Res. 26:1992;299-317.
19. 3 Antagonists and Benzodiazepines: Their Comparative Behavioural Pharmacology. 1991;59-105 Wiley, England.
20. Barrett J.E., Vanover K.E. 5-HT receptors as targets for the development of novel anxiolytic drug models, mechanisms and future directions. Psychopharmacology. 112:1993;1-12.
21. Bartfai T., Fisone G., Langel U. Galanin and galanin antagonists: molecular and biochemical perspectives. Trends Pharmacol. Sci. 13:1992;312-317.
22. Bartoszyk G.D. Anxiolytic effects of dopamine receptor ligands: I. Involvement of dopamine autoreceptors. Life Sci. 62:1998;649-663.
23. Baumgarten H.G., Grozdanovic Z. Anatomy of central serotoninergic projections systems. Handbook Exp. Pharmacol. 129:1997;41-89.
24. Beaufour C.C., Le Bihan C., Hamon M., Thiébot M.-H. Extracellular dopamine in the rat prefrontal cortex during reward-, punishment-, and novelty-associated behaviour. Effects of diazepam. Pharmacol. Biochem. Behav. 69:2001;133-143.
25. Beaufour C.C., Le Bihan C., Hamon M., Thiébot M.-H. Extracellular serotonin is enhanced in the striatum, but not in the dorsal hippocampus or prefrontal cortex, in rats subjected to an operant conflict procedure. Behav. Neurosci. 115:2001;125-137.
26. 1A receptor antagonist WAY100635 on periaqueductal grey-induced defence behaviour. J. Psychopharmacol. 11:1997;35-40.
27. 1 hippocampal area. Gen. Pharmacol. 28:1997;435-441.
28. Belzung C. The genetic basis of the pharmacological effects of anxiolytics: a review based on rodent models. Behav. Pharmacol. 12:2001;451-460.
29. Belzung C., Griebel G. Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav. Brain Res. 125:2001;141-149.
30. Bennett D.A., Amrick C.L. 2-Amino-7-phosphonoheptanoic acid (AP7) produces discriminative stimuli and anticonflict effects similar to diazepam. Life Sci. 39:1986;2455-2461.
31. 3 antagonists in neuropsychiatric disorders. CNS Drugs. 3:1995;363-392.
32. Benvenga M.J., Ornstein P.L., Leander D.J. Schedule-controlled behavioral effects of the selective 2-amino-3-(5-methyl-3-hydroxy-isoxazol-4-yl) propanoic acid antagonist LY 293558 in pigeons. J. Pharmacol. Exp. Ther. 275:1995;164-170.
33. Benvenga M.J., Overshiner C.D., Monn J.A., Leander D.J. Disinhibitory effects of LY354740, a new mGluR2 agonist, on behaviors suppressed by electric shock in rats and pigeons. Drug Dev. Res. 47:1999;37-44.
34. B receptors. Trends Neurosci. 24:2001;277-282.
35. Bing O., Möller C., Engel J.A., Söderpalm B., Heilig M. Anxiolytic-like action of centrally administered galanin. Neurosci. Lett. 164:1993;17-20.
36. Bischoff S., Leonhard S., Reymann N., Schuler V., Shigemoto R., Kaupmann K., Bettler B. Spatial distribution of GABA(B)R1 receptor mRNA and binding sites in the rat brain. J. Comp. Neurol. 412:1999;1-16.
37. Bitsios P., Szabadi E., Bradshaw C.M. The effects of clonidine on the fear-inhibited light reflex. J. Psychopharmacol. 12:1998;137-145.
38. Bjertnaes A., Block J.M., Hafstad P.E., Holte M., Ottemo I., Larsen T., Pindek R.M., Steffensen K., Stulemeijer S.M. A multicentre placebo-controlled trial comparing the efficacy of mianserin and chlordiazepoxide in general practice patients with primary anxiety. Acta Psychiatr. Scand. 66:1982;199-207.
39. Blanchard D.C., Shepherd J.K., Rodgers R.J., Blanchard R.J. Evidence for differential effects of 8-OH-DPAT on male and female rats in the anxiety/defense test battery. Psychopharmacology. 106:1992;531-539.
40. Blednov Y.A., Stoffel M., Chang S.R., Harris R.A. GIRK2 deficient mice: evidence for hyperactivity and reduced anxiety. Physiol. Behav. 74:2001;109-117.
41. Bonanno G., Raiteri M. Pharmacological discrimination between gamma-aminobutyric acid type B receptors regulating cholecystokinin and somatostatin release from rat neocortex synaptosomes. Mol. Pharmacol. 46:1994;558-562.
42. Borowski T.B., Kokkinidis L. Contribution of ventral tegmental area dopamine neurons to expression of conditioned fear: effects of electrical stimulation, excitotoxin lesions, and quinpirole infusion on potentiated startle in rats. Behav. Neurosci. 110:1996;1349-1364.
43. Braissant O., Gotoh T., Loup M., Mori M., Bachmann C. L-Arginine uptake, the citrulline-NO cycle and arginase II in the rat brain: an in situ hybridization study. Mol. Brain Res. 70:1999;231-241.
44. Branchek T.A., Smith K.E., Gerald C., Walker M.W. Galanin receptor subtypes. Trends Pharmacol. Sci. 21:2000;109-117.
45. Bräuner-Osborne H., Egebjerg J., Nielsen E.O., Madsen U., Krogsgaard-Larsen P. Ligands for glutamate receptors: design and therapeutic prospects. J. Med. Chem. 43:2000;2609-2645.
46. Bremner J.D., Krystal J.H., Southwick S.M., Charney D.S. Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies. Synapse. 23:1996;28-38.
47. Bremner J.D., Krystal J.H., Southwick S.M., Charney D.S. Noradrenergic mechanisms in stress and anxiety: II. Clinical studies. Synapse. 23:1996;39-51.
48. Britton K.T., Morgan J., Rivier J., Vale W., Koob G. Chlordiazepoxide attenuates response suppression induced by corticotropin-releasing factor in the conflict test. Psychopharmacology. 86:1985;170-174.
49. Britton K.T., Page M., Baldwin H., Koob G.F. Anxiolytic activity of steroid anesthetic alphaxalone. J. Pharmacol. Exp. Ther. 258:1991;124-129.
50. Britton K.T., Southerland S., Van Uden E., Kirby D., Rivier J., Koob G. Anxiolytic activity of NPY receptor agonists in the conflict test. Psychopharmacology. 132:1997;6-13.
51. Britton K.T., Akwa Y., Spina M.G., Koob G.F. Neuropeptide Y blocks anxiogenic-like behavioral action of corticotropin-releasing factor in an operant conflict test and elevated plus maze. Peptides. 21:2000;37-44.
52. Brocco M., Koek W., Degryse A.-D., Colpaert F.C. Comparative studies on the anti-punishment effects of chlordiazepoxide, buspirone and ritanserin in the pigeon. Geller-Seifter and Vogel conflict procedures. Behav. Pharmacol. 1:1990;403-418.
53. Broersen L.M., Abbate F., Feenstra M.G.P., de Bruin J.P.C., Heinsbroek R.P.W., Olivier B. Prefrontal dopamine is directly involved in the anxiogenic interoceptive cue of pentylenetetrazol but not in the interoceptive cue of chlordiazepoxide in the rat. Psychopharmacology. 149:2000;366-376.
54. Broocks A., Bandelow B., George A., Jestrabeck C., Opitz M., Bartmann U., Gleiter C.H., Meineke I., Roed I.-S., Rüther E., Hajak G. Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder. Int. Clin. Psychopharmacol. 15:2000;153-161.
55. 1F receptor messenger RNA in rodent and primate brain. Neuropharmacology. 33:1994;367-386.
56. Canto-de-Souza A., Nunes-de-Souza R.L., Rodgers R.J. Anxiolytic-like effect of WAY-100635 microinfusions into the median (but not dorsal) raphe nucleus in mice exposed to the plus-maze: influence of prior test experience. Brain Res. 928:2002;50-59.
57. 1A. Pharmacol. Biochem. Behav. 58:1997;583-591.
58. Carboni E., Wieland S., Lan N.C., Gee K.W. Anxiolytic properties of endogenously occurring pregnanediols in two rodent models of anxiety. Psychopharmacology. 126:1996;173-178.
59. A receptor agonist. Psychopharmacology. 94:1988;84-91.
60. Carli M., Prontera C., Samanin R. Evidence that central 5-hydroxytryptaminergic neurons are involved in the anxiolytic activity of buspirone. Br. J. Pharmacol. 96:1989;829-836.
61. Carobrez A.P., Teixeira K.V., Graeff F.G. Modulation of defensive behavior by periaqueductal gray NMDA/glycine-B receptor. Neurosci. Biobehav. Rev. 25:2001;697-709.
62. Carlson J.N., Haskew R., Wacker J., Maisonneuve I.M., Glick S.D., Jerussi T.P. Sedative and anxiolytic effects of zopiclone's enantiomers and metabolite. Eur. J. Pharmacol. 415:2001;181-189.
63. Cavazzuti E., Bertolini A., Vergoni A.V., Arletti R., Poggioli R., Forgione A., Benelli A. L-Sulpiride, at a low, non-neuroleptic dose, prevents conditioned fear stress-induced freezing behavior in rats. Psychopharmacology. 143:1999;20-23.
64. A, and glutamate receptors. J. Neurosci. 21:2001;9917-9929.
65. 1A receptors mediate the effects of ipsapirone on punished responding in rats. Eur. J. Pharmacol. 284:1995;249-255.
66. 1A receptors in the dorsal raphe and dorsal hippocampus in anxiety assessed by the behavioral effects of 8-OH-DPAT and S 15535 in a modified Geller-Seifter conflict model. Neuropharmacology. 39:2000;1037-1043.
67. Charney D.S., Deutch A. A functional neuroanatomy of anxiety and fear: implication for the pathophysiology and treatment of anxiety disorders. Crit. Rev. Neurobiol. 10:1996;419-446.
68. Charney D.S., Heninger G.R., Redmond D.E. Yohimbine induced anxiety and increased noradrenergic function in humans: effects of diazepam and clonidine. Life Sci. 33:1983;19-29.
69. Charrier D., Dangoumau L., Puech A.J., Hamon M., Thiébot M.-H. Failure of CCK receptor ligands to modify anxiety-related behavioural suppression in an operant conflict paradigm in rats. Psychopharmacology. 121:1995;127-134.
70. 1)-like immunoreactivity in the mouse brain: light microscopy analysis using an antibody directed against the C-terminus. J. Comp. Neurol. 420:2000;305-323.
71. 1B receptors in the anticonflict effect of m-CPP in rats. J. Neural Transm. [Gen. Sect.]. 87:1992;87-96.
72. 1A receptors in the anticonflict effect of ipsapirone in rats. Neuropharmacology. 30:1991;703-709.
73. Chojnacka-Wójcik E., Tatarczyńska E., Dereń-Wesolek A. Effect of glycine on antidepressant- and anxiolytic-like action of 1-aminocyclopropanecarboxylic acid (ACPC) in rats. Pol. J. Pharmacol. 48:1996;627-629.
74. Chojnacka-Wójcik E., Tatarczýnska E., Pilc A. The anxiolytic-like effect of metabotropic glutamate receptor antagonists after intrahippocampal injection in rats. Eur. J. Pharmacol. 319:1997;153-156.
75. Chopin P., Briley M. Animal models of anxiety: the effect of compounds that modify 5-HT neurotransmission. Trends Pharmacol. Sci. 8:1987;383-388.
76. 1B/1D receptor ligands. Pharmacol. Ther. 62:1994;385-405.
77. Christopoulos A., El-Fakahany E.E. The generation of nitric oxide by G protein-coupled receptors. Life Sci. 64:1999;1-15.
78. 2C receptor protein in the rat CNS. Neuropharmacology. 39:2000;123-132.
79. Coco M.L., Kuhn C.M., Ely T.D., Kilts C.D. Selective activation of mesoamygdaloid dopamine neurons by conditioned stress: attenuation by diazepam. Brain Res. 590:1992;39-47.
80. 2-adrenoceptor mediation. Psychopharmacology. 118:1995;425-436.
81. Commissaris R.L., Lyness W.H., Rech R.H. The effects of D-lysergic acid diethylamide (LSD), 2,5-dimethoxy-4-methylamphetamine (DOM), pentobarbital and methaqualone on punished responding in control and 5,7-dihydroxytryptamine-treated rats. Pharmacol. Biochem. Behav. 14:1981;617-623.
82. Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 37:1997;205-237.
83. 2 receptors and anxiety. Behav. Pharmacol. 6(Suppl. 1):1995;35.
84. Contarino A., Heinrichs S.C., Gold L.H. Understanding corticotropin releasing factor neurobiology: contributions from mutant mice. Neuropeptides. 33:1999;1-12.
85. Corbett R., Dunn R.W. Effects of HA-966 on conflict, social interaction and plus-maze behaviors. Drug Dev. Res. 24:1991;205-301.
86. Corbett R., Dunn R.W. Effects of 5,7 dichlorokynurenic acid on conflict, social interaction and plus maze behaviors. Neuropharmacology. 32:1993;461-466.
87. 2A receptor in the central nervous system of adult rat. J. Comp. Neurol. 409:1999;187-209.
88. 3 receptor agonist and antagonists for alteration of aversive behaviour in the mouse. Br. J. Pharmacol. 96:1989;325-332.
89. Costall B., Domeney A.M., Hughes J., Kelly M.E., Naylor R.J., Woodruff G.N. Anxiolytic effects of CCK-B antagonists. Neuropeptides. 19:1991;65-73.
90. 2A receptor antagonists inhibit potassium-stimulated γ-aminobutyric acid release in rat frontal cortex. Eur. J. Pharmacol. 309:1996;25-31.
91. Crawley J., Glowa J.R., Maajewska M.D., Paul S.M. Anxiolytic activity of an endogenous adrenal steroid. Brain Res. 398:1986;382-385.
92. Crespi F., Wright I.K., Möbius C. Isolation rearing of rats alters release of 5-hydroxytryptamine and dopamine in the frontal cortex: an in vivo electrochemical study. Exp. Brain. Res. 88:1992;495-501.
93. Crestani F., Löw K., Keist R., Mandelli M.-J., Möhler H., Rudolph U. Molecular targets for the myorelaxant action of diazepam. Mol. Pharmacol. 59:2001;442-445.
94. Culpepper L. Generalized anxiety disorder in primary care: emerging issues in management and treatment. J. Clin. Psychiatry. 63:2002;35-42.
95. Czlonkowska A., Siemiatkowski M., Plaźnik A. Some behavioral effects of AMPA/kainate receptor agonist and antagonists. J. Physiol. Pharmacol. 48:1997;479-488.
96. 3H-muscimol binding in the brain. Pharmacol. Biochem. Behav. 63:1999;639-646.
97. Dalvi A., Rodgers R.J. GABAergic influences on plus-maze behaviours in mice. Psychopharmacology. 128:1996;380-397.
98. Danysz W., Parsons C.G. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol. Rev. 50:1998;597-664.
99. 2 receptor-deficient mice. Neuropsychopharmacology. 25:2001;690-698.
100. 1d-adrenergic receptor mRNA in the rat brain and spinal cord. J. Chem. Neuroanat. 13:1997;23-26.
101. 1B receptor knockout mice. Eur. J. Pharmacol. 439:2002;93-100.
102. DeMartinis N., Rynn M., Rickels K., Mandos L. Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder. J. Clin. Psychiatry. 61:2000;91-94.
103. De Souza M., Schenberg L.C., Carobrez A.P. NMDA-coupled periaqueductal gray glycine receptors modulate anxioselective drug effects on plus-maze performance. Behav. Brain Res. 90:1998;157-165.
104. 1A receptor agonists: recent developments and controversial issues. Psychopharmacology. 121:1995;1-26.
105. Deakin J.F. Depression and 5-HT. Int. Clin. Psychopharmacol. 6:1991;23-28.
106. Deakin J.F.W., Graeff F.G. 5-HT and mechanisms of defence. J. Psychopharmacol. 5:1991;305-315.
107. 2C) receptors. Neuropharmacology. 39:2000;1114-1117.
108. 1A receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely moving rats. A comparison with other anxiolytic agents. Psychopharmacology. 152:2000;55-66.
109. Depoortere H., Zivkovic B., Lloyd K.G., Sanger D.J., Perrault G., Langer S.Z., Bartholini G. Zolpidem, a novel nonbenzodiazepine hypnotic: I. Neuropharmacological and behavioral effects. J. Pharmacol. Exp. Ther. 237:1986;649-658.
110. 3 receptors and GABAergic neurons inhibiting acetylcholine release in rat entorhinal cortex slices. Brain Res. 81:1998;228-232.
111. Doble A. New insights into the mechanism of action of hypnotics. J. Psychopharmacology. 13(4, Suppl. 1):1999;S11-S20.
112. 3 receptor. Neuroscience. 95:2000;881-892.
113. Drugan R.C., Skolnick P., Paul S.M., Crawley J.N. Low doses of muscimol produce anticonflict actions in the lateral septum of the rat. Neuropharmacology. 25:1986;203-205.
114. 3B receptor subunit. J. Biol. Chem. 274:1999;30799-30810.
115. 1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus-maze. Eur. J. Pharmacol. 169:1989;1-10.
116. G-nitro-L-arginine are anxiolytic and are devoid of benzodiazepine side-effects in rats. Am. Soc. Neurosci. Abst. 21:1995;1384.
117. Durel L.A., Krantz D.S., Barretti J.E. The antianxiety effect of beta-blockers on punished responding. Pharmacol. Biochem. Behav. 25:1986;371-374.
118. 2B receptor protein in the rat central nervous system. Neuroscience. 76:1997;323-329.
119. 2B receptors in the medial amygdala causes anxiolysis in the social interaction test in the rat. Neuropharmacology. 36:1997;601-608.
120. Egberongbe Y.I., Gentleman S.M., Falkai P., Bogerts B., Polak J.M., Roberts G.W. The distribution of nitric oxide synthase immunoreactivity in the human brain. Neuroscience. 59:1994;561-578.
121. Eison A.S., Eison M.S., Stanley M., Riblet L.A. Serotonergic mechanisms in the behavioral effects of buspirone and gepirone. Pharmacol. Biochem. Behav. 24:1986;701-707.
122. Engel J.A., Hjorth S., Svensson K., Carlsson A., Liljequist S. Anticonflict effect of the putative serotonin receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). Eur. J. Pharmacol. 105:1984;365-368.
123. Engel J.A., Egbe P., Liljequist S., Söderpalm B. Effects of amperozide in two animal models of anxiety. Pharmacol. Toxicol. 64:1989;429-433.
124. Espejo E.F. Selective dopamine depletion within the medial prefrontal cortex induces anxiogenic-like effects in rats placed on the elevated plus maze. Brain Res. 762:1997;281-284.
125. Falkenstein E., Tillmann H.-C., Christ M., Feuring M., Wehling M. Multiple actions of steroid hormones - a focus on rapid, nongenomic effects. Pharmacol. Rev. 52:2000;513-555.
126. Fedele E., Conti A., Raiteri M. The glutamate receptor/NO/cyclic GMP pathway in the hippocampus of freely moving rats: modulation by cyclothiazide, interaction with GABA and behavioural consequences. Neuropharmacology. 36:1997;1393-1403.
127. A receptor channels through activation of anchored protein kinase C in prefrontal cortical neurons. J. Neurosci. 21:2001;6502-6511.
128. 1A compounds by GABA-benzodiazepine agents in rats. Pharmacol. Biochem. Behav. 60:1998;27-32.
129. File S.E., Andrews N., Wu P.Y., Zharkovsky A., Zangrossi H. Jr. Modification of chlordiazepoxide's behavioural and neurochemical effects by handling and plus-maze experience. Eur. J. Pharmacol. 218:1992;9-14.
130. File S.E., Kenny P.J., Cheeta S. The role of dorsal hippocampal serotonergic and cholinergic systems in the modulation of anxiety. Pharmacol. Biochem. Behav. 66:2000;65-72.
131. 3) receptor antagonists. Pol. J. Pharmacol. Pharm. 44:1992;261-269.
132. Flores P., Pellón R. Antipunishment effects of diazepam on two levels of suppression of schedule-induced drinking in rats. Pharmacol. Biochem. Behav. 67:2000;207-214.
133. Fontana D.J., McCloskey T., Jolly S.K., Commissaris R.L. The effects of beta-antagonists and anxiolytics on conflict behavior in the rat. Pharmacol. Biochem. Behav. 32:1989;807-813.
134. Fontana D.J., Schefke D.M., Commissaris R.L. Acute versus chronic clonidine treatment effects on conflict behavior in the rat. Behav. Pharmacol. 1:1990;201-208.
135. A-receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits. J. Comp. Neurol. 359:1995;154-194.
136. Gacsalyi I., Schmidt E., Gyertyan I., Vasar E., Lang A., Haapalinna A., Fekete M., Hietala J., Syvälahti E., Tuomainen P., Männistö P.T. Receptor binding profile and anxiolytic-type activity of deramciclane (EGIS-3886) in animals models. Drug Dev. Res. 40:1997;333-348.
137. Gasior M., Carter R.B., Witkin J.M. Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders. Trends Pharmacol. Sci. 20:1999;107-112.
138. Geller I., Seifter J. The effects of meprobamate, barbiturate, D-amphetamine and promazine on experimentally induced conflict in the rat. Psychopharmacologia. 1:1960;482-492.
139. 2-like dopamine receptor mediation of social-emotional reactivity in a mouse model of anxiety: strain and experience effects. Neuropsychopharmacology. 18:1998;210-221.
140. 2 dopamine receptor agonists differentially modulate isolation-induced social-emotional reactivity in mice. Behav. Brain Res. 114:2000;107-117.
141. 2C receptors but not by sympathomimetic effects. Neuropharmacology. 33:1994;457-465.
142. Gleeson S., Ahlers S.T., Mansbach R.S., Foust J.M., Barrett J.E. Behavioral studies with anxiolytic drugs: VI. Effects on punished responding of drugs interacting with serotonin receptor subtypes. J. Pharmacol. Exp. Ther. 250:1989;809-817.
143. 1B receptors. Neuropsychopharmacology. 21:1999;268-284.
144. 3H-magnetic resonance spectroscopy. Arch. Gen. Psychiatry. 58:2001;556-561.
145. 1A and benzodiazepine receptors in the basolateral amygdala modulate anxiety in the social interaction test, but not in the elevated plus-maze test. Brain Res. 732:1996;145-153.
146. Gorman J.M. Treatment of generalized anxiety disorder. J. Clin. Psychiatry. 63(Suppl. 8):2002;17-23.
147. Gower A.J., Tricklebank M.D. Alpha-2-adrenoceptor antagonist activity may account for the effects of buspirone in an anticonflict test in the rat. Eur. J. Pharmacol. 155:1988;129-137.
148. Graeff F.G., Guimarães F.S., de Andrade T.G.C.S., Deakin J.F.W. Role of 5-HT in stress, anxiety and depression. Pharmacol. Biochem. Behav. 54:1996;129-141.
149. Graeff F.G., Ferreira Netto C., Zangrossi H. Jr. The elevated T-maze as an experimental model of anxiety. Neurosci. Biobehav. Rev. 23:1998;237-246.
150. 2 receptor binding characteristics in cynomolgus monkeys assessed with positron emission tomography. Synapse. 29:1998;80-83.
151. 2 receptors impairs emotional learning measured with fear-potentiated startle. Brain Res. 899:2001;218-226.
152. Griebel G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol. Ther. 82:1999;1-61.
153. 1A receptor blockers as potential drug candidates for the treatment of anxiety disorders. Drug News Perspect. 12:1999;484-490.
154. 2 receptor subtype antagonists in rat and mouse models of anxiety. Neuropharmacology. 36:1997;793-802.
155. Griebel G., Perrault G., Sanger D.J. CCK receptor antagonists in animal models of anxiety: comparison between exploration tests, conflict procedures and a model based on defensive behaviours. Behav. Pharmacol. 8:1997;549-560.
156. Griebel G., Perrault G., Sanger D.J. Characterization of the behavioural profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents: comparison with diazepam and buspirone. Psychopharmacology. 138:1998;55-66.
157. Griebel G., Perrault G., Letang V., Granger P., Avenet P., Shoemaker H., Sanger D.J. New evidence that the pharmacological effects of benzodiazepine receptor ligands can be associated with activities at different BZ (ω) receptor subtypes. Psychopharmacology. 146:1999;205-213.
158. Griebel G., Perrault G., Tan S., Shoemaker H., Sanger D.J. Comparison of the pharmacological properties of classical and novel BZ-ω receptor ligands. Behav. Pharmacol. 10:1999;483-495.
159. 1A receptor antagonist in three rat models of anxiety. Neuropharmacology. 39:2000;1848-1857.
160. Griebel G., Perrault G., Simiand J., Cohen C., Granger P., Decobert M., Françon D., Avenet P., Depoortere H., Tan S., Oblin A., Shoemaker H., Evanno Y., Sevrin M., George P., Scatton B. SL651498: an anxioselective
161. 1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc. Natl. Acad. Sci. U. S. A. 99:2002;6370-6375.
162. Griebel G., Simiand J., Steinberg R., Jung M., Gully D., Roger P., Geslin M., Scatton B., Maffrand J.-P., Soubrié P. 4-(2-Chloro-4-metoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4- methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor1 receptor antagonist: II. Characterization in rodent models of stress-related disorders. J. Pharmacol. Exp. Ther. 301:2002;333-345.
163. Grobin A.C., Deutch A.Y. Dopaminergic regulation of extracellular GABA levels in the prefrontal cortex. J. Pharmacol. Exp. Ther. 285:1998;350-357.
164. Groenink L., Joordens J.E., Hijzen T.H., Dirks A., Olivier B. Infusion of flesinoxan into the amygdala blocks the fear-potentiated startle. NeuroReport. 11:2000;2285-2289.
165. 1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature. 416:2002;396-400.
166. Guidotti A., Costa E. Can the antidysphoric and anxiolytic profiles of selective serotonin reuptake inhibitors be related to their ability to increase brain 3α,5α-tetrahydroprogesterone (allopregnanolone) availability? Biol. Psychiatry. 44:1998;865-873.
167. Halasy K., Miettinen R., Szabat E., Freund T.F. GABAergic interneurons are the major postsynaptic targets of median raphe afferents in the rat dentate gyrus. Eur. J. Neurosci. 4:1992;144-153.
168. Hammack S.E., Richey K.J., Schmid M.J., LoPresti M.L., Watkins L.R., Maier S.F. The role of corticotropin-releasing hormone in the dorsal raphe nucleus in mediating the behavioral consequences of uncontrollable stress. J. Neurosci. 22:2002;1020-1026.
169. Harkin A.J., Bruce K.H., Craft B., Paul I.A. Nitric oxide synthase inhibitors have antidepressant-like properties in mice: I. Acute treatments are active in the forced swim test. Eur. J. Pharmacol. 372:1999;207-213.
170. 1A agonists in rats: a new model for evaluating anxiolytic-like activity. J. Psychopharmacol. 8:1994;227-237.
171. Heilig M., Söderpalm B., Engel J.A., Widerlöv E. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology. 98:1989;524-529.
172. Heilig M., Koob G.F., Ekman R., Britton K.T. Corticotropin-releasing factor and neuropeptide Y: role in emotional integration. Trends Neurosci. 17:1994;80-85.
173. Hein L., Altman J.D., Kobilka B.K. Two functionally distinct α-2-adrenergic receptors regulate sympathetic neurotransmission. Nature. 402:1999;181-184.
174. 2C receptor null mutant mice. Am. Soc. Neurosci. Abstr. 24:1998;602.
175. 1A receptor mutant mice. Proc. Natl. Acad. Sci. U. S. A. 95:1998;15049-15054.
176. Helton D.R., Tizzano J.P., Monn J.A., Schoepp D.D., Kallman M.J. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J. Pharmacol. Exp. Ther. 284:1998;651-660.
177. Hernando F., Schoots O., Lolait S.J., Burbach J.P. Immunohistochemical localization of the vasopressin V1b receptor in the rat brain and pituitary gland: anatomical support for its involvement in the central effects of vasopressin. Endocrinology. 142:2001;1659-1668.
178. A receptors. Mol. Neurobiol. 18:1998;35-86.
179. Hieble J.P., Bondinell W.E., Ruffolo R.R. Alpha- and beta-adrenoceptors: from the gene to the clinic: 1. Molecular biology and adrenoceptor subclassification. J. Med. Chem. 38:1995;3415-3444.
180. 1-like and GABA receptors in the dorsal raphé nucleus of the rat. Neuropharmacology. 27:1988;993-1001.
181. 3 receptor antagonists. Psychopharmacology. 104:1991;545-551.
182. 1A receptor agonists in two models of anxiety after dorsal raphe injection. Psychopharmacology. 106:1992;261-267.
183. Hjorth S., Engel J.A., Carlsson A. Anticonflict effects of low doses of the dopamine agonist apomorphine in the rat. Pharmacol. Biochem. Behav. 24:1986;237-240.
184. Hjorth S., Söderpalm B., Engel J.A. Biphasic effect of L-5-HTP in the Vogel conflict model. Psychopharmacology. 92:1987;96-99.
185. Hjorth S., Carlsson A., Engel J.A. Anxiolytic-like action of the 3-PPP enantiomers in the Vogel conflict paradigm. Psychopharmacology. 92:1987;371-375.
186. Hodges H., Green S., Glenn B. Evidence that amygdala is involved in benzodiazepine and serotonergic effects on punished responding but not on discrimination. Psychopharmacology. 92:1987;491-504.
187. Huang Y.Y., Kandel E.R. Modulation of both the early and the late phase of mossy fiber LTP by the activation of β-adrenergic receptors. Neuron. 16:1996;611-617.
188. 2C receptors. Neuropharmacology. 35:1996;1355-1363.
189. Izzo E., Auta J., Impagnatiello F., Pesold C., Guidotti A., Costa E. Glutamic acid decarboxylase and glutamate receptor changes during tolerance and dependence to benzodiazepines. Proc. Natl. Acad. Sci. U. S. A. 98:2001;3483-3488.
190. Jackson D.M., Westlind-Danielsson A. Dopamine receptors: molecular biology, biochemistry and behavioural aspects. Pharmacol. Ther. 64:1994;291-370.
191. 3 receptors in inhibitory circuits of the primate cerebral cortex. J. Comp. Neurol. 417:2000;337-348.
192. 1C receptors in the serotonergic control of periaqueductal gray induced aversion in rats. Psychopharmacology. 100:1990;372-376.
193. 1A receptor agonist flesinoxan increases aversion in a model of panic-like anxiety in rats. J. Psychopharmacol. 13:1999;166-170.
194. Jessa M., Nazar M., Bidzinski A., Plaznik A. The effects of repeated administration of diazepam, MK-801 and CGP 37849 on rat behavior in two models of anxiety. Eur. Neuropsychopharmacol. 6:1996;55-61.
195. Johnston A.L., File S.E. Yohimbine's anxiogenic action: evidence for noradrenergic and dopaminergic sites. Pharmacol. Biochem. Behav. 32:1988;151-156.
196. 3-receptor antagonist. Br. J. Pharmacol. 93:1988;985-993.
197. 3 receptor as a therapeutic target for antipsychotic and antiparkinsonnian drugs. Pharmacol. Ther. 90:2001;231-259.
198. Kable J.W., Murrin L.C., Bylund D.B. In vivo gene modification elucidates subtype-specific functions of alpha(2)-adrenergic receptors. J. Pharmacol. Exp. Ther. 293:2000;1-7.
199. 3 agonists disrupt social behavior in rats. Brain Res. 721:1996;229-232.
200. Kalivas P.W., Duffy P. Selective activation of dopamine transmission in the shell of the nucleus accumbens by stress. Brain Res. 675:1995;325-328.
201. Karcz-Kubicha M., Jessa M., Nazar M., Plaznik A., Hartmann S., Parsons C.G., Danysz W. Anxiolytic activity of glycine-B antagonists and partial agonists - no relation to intrinsic activity in the patch clamp. Neuropharmacology. 36:1997;1355-1367.
202. Karolyi I.J., Burrows H.L., Ramesh T.M., Nakajima M., Lesh J.S., Seong E., Camper S.A., Seasholtz A.F. Altered anxiety and weight gain in corticotropin-releasing hormone-binding protein-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 96:1999;11595-11600.
203. Karreman M., Moghaddam B. Effect of a pharmacological stressor on glutamate efflux in the prefrontal cortex. Brain Res. 716:1996;180-182.
204. Kash S.F., Tecott L.H., Hodge C., Baekkeskov S. Increased anxiety and altered responses to anxiolytics in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. Proc. Natl. Acad. Sci. U. S. A. 96:1999;1698-1703.
205. Kask A., Harro J., von Horsten S., Redrobe J.P., Dumont Y., Quirion R. The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neurosci. Biobehav. Rev. 26:2002;259-283.
206. 1A agonistic anxiolytic. Neuropharmacology. 30:1991;475-480.
207. Kawahara H., Kawahara Y., Westerink B.H.C. The role of afferents to the locus coeruleus in the handling stress-induced increase in the release of noradrenaline in the medial prefrontal cortex: a dual-probe microdialysis study in the rat brain. Eur. J. Pharmacol. 387:2000;279-286.
208. 2B receptor antagonist, in two conflict models of anxiety. Psychopharmacology. 118:1995;178-182.
209. 2B receptor agonist, BW 723C86, on three rat models of anxiety. Br. J. Pharmacol. 117:1996;1443-1448.
210. 2B receptor antagonist with anxiolytic-like properties. Br. J. Pharmacol. 117:1996;427-434.
211. 2C receptor antagonist. Neuropharmacology. 36:1997;609-620.
212. 2B receptor mediated. Neuropharmacology. 37:1998;1603-1610.
213. 2C receptor agonist, in three animal models of anxiety. Eur. J. Pharmacol. 387:2000;197-204.
214. Ketelaars C.E.J., Bollen E.L., Rigter H., Bruinvels J. GABA-B receptor activation and conflict behaviour. Life Sci. 42:1988;933-942.
215. Kew J.N.C., Koester A., Moreau J.-L., Jenck F., Ouagazzal A.-M., Mutel V., Richards J.G., Trube G., Fischer G., Montkowski A., Hundt W., Reinscheid R.K., Pauly-Evers M., Kemp J.A., Bluethmann H. Functional consequences of reduction in NMDA receptor glycine affinity in mice carrying targeted point mutations in the glycine binding site. J. Neurosci. 20:2000;4037-4049.
216. 1A receptor ligands in a modified Geller-Seifter conflict model in the rat. Eur. J. Pharmacology. 325:1997;121-128.
217. B receptor partial agonist. D-Cycloserine, in rats. Pharmacological analysis. Psychopharmacology. 152:2000;224-228.
218. Klodzińska A., Tatarczyńska E., Chojnacka-Wójcik E., Pilc A. Anxiolytic-like effects of group I metabotropic glutamate antagonist 2-methyl-6-(phenylethyl)-pyridine (MPEP) in rats. Pol. J. Pharmacol. 52:2000;463-466.
219. Kõks S., Beljajev S., Koovit I., Abramov U., Bourin M., Vasar E. 8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze. Psychopharmacology. 153:2001;365-372.
220. Kostowski W., Plaznik A., Stefanski R. Intra-hippocampal buspirone in animal models of anxiety. Eur. J. Pharmacology. 168:1989;393-396.
221. Kotlinska J., Liljequist S. A characterization of anxiolytic-like actions induced by the novel NMDA/glycine site antagonist, L701,324. Psychopharmacology. 135:1998;175-181.
222. Kotlinska J., Liljequist S. The putative AMPA receptor antagonist, LY326325, produces anxiolytic-like effects without altering locomotor activity in rats. Pharmacol. Biochem. Behav. 60:1998;119-124.
223. Koyama S., Kubo C., Rhee J.-S., Akaike N. Presynaptic serotonergic inhibition of GABAergic synaptic transmission in mechanically dissociated rat basolateral amygdala neurons. J. Physiol. 518:1999;525-538.
224. Krasowski M.D., Koltchine V.V., Rick C.E., Ye Q., Finn S.E., Harrison N.L. Propofol and other intravenous anesthetics have sites of action on the γ-aminobutyric acid type A receptor distinct from that for isoflurane. Mol. Pharmacol. 53:1998;530-538.
225. Krystal J.H., McDougle C.J., Woods S.W., Price L.H., Heninger G.R., Charney D.S. Dose-response relationship for oral idazoxan effects in healthy human subjects: comparison with oral yohimbine. Psychopharmacology. 108:1992;313-319.
226. Kunishima N., Shimada Y., Tsuji Y., Sato T., Yamamoto M., Kumasaka T., Nakanishi S., Jingami H., Morikawa K. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature. 407:2000;971-977.
227. Kuribara H., Fujiwara S., Yasuda H., Tadokoro S. The anticonflict effect of MK-801, an NMDA antagonist: investigation by punishment procedure in mice. Jpn. J. Pharmacol. 54:1990;250-252.
228. 2-antagonists idazoxan and rauwolscine but not yohimbine or piperoxan are anxiolytic in the Vogel lick-shock conflict paradigm following intravenous administration. Life Sci. 54:1994;PL179-PL184.
229. Laakman G., Schüle C., lorkowski G., Baghai T., Kuhn K., Ehrentraut S. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology. 136:1998;357-366.
230. Lambert J.J., Belelli D., Hill-Venning C., Peters J.A. Neurosteroids and GABA receptor function. Trends Pharmacol. Sci. 16:1995;295-303.
231. Lan N.C., Gee K.W. Epalons as promising therapeutic agents. Drug News Perspect. 10:1997;604-611.
232. Lapiz M.D.S., Mateo Y., Durkin S., Parker T., Marsden C.A. Effects of central noradrenaline depletion by the selective neurotoxin DSP-4 on the behaviour of the isolated rat in the elevated plus maze and water maze. Psychopharmacology. 155:2001;251-259.
233. Le Moal M., Simon H. Mesocorticolimbic dopaminergic network: functional and regulatory roles. Physiol. Rev. 71:1991;155-234.
234. Lees G. Pharmacology of AMPA/Kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders. Drugs. 59:2000;33-78.
235. Lesch K.P. Molecular foundation of anxiety disorders. J. Neural Transm. 108:2001;717-746.
236. Li X.B., Inoue T., Hashimoto S., Koyama T. Effect of chronic administration of flesinoxan and fluvoxamine on freezing behavior induced by conditioned fear. Eur. J. Pharmacol. 425:2001;43-50.
237. Liang F., Hatanaka Y., Saito H., Yamamori T., Hashikawa T. Differential expression of γ-aminobutyric acid type B receptor-1a and -1b mRNA variants in GABA and non-GABAergic neurons of the rat brain. J. Comp. Neurol. 416:2000;475-495.
238. Liljequist S., Engel J.A. Reversal of the anti-conflict action of valproate by various GABA and benzodiazepine antagonists. Life Sci. 34:1984;2525-2533.
239. 1B receptor stimulation in the rat elevated plus-maze. Pharmacol. Biochem. Behav. 71:2002;581-587.
240. Lines C., Challenor J., Traub M. Cholecystokinin and anxiety in normal volunteers: an investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype B antagonist L-365,260. Br. J. Clinical. Pharmacol. 39:1995;235-242.
241. 2 receptors activate local GABA inhibitory inputs to serotonergic neurons of the dorsal raphe nucleus. Brain Res. 873:2000;34-45.
242. 1b vasopressin receptor gene. Proc. Natl. Acad. Sci. U. S. A. 92:1995;6783-6787.
243. 1b receptor knockout mouse. Am. Soc. Neurosci. Abstr. 26:2000;2406.
244. 3H]MDL 100,907. Naunyn-Schmiedberg's Arch. Pharmacol. 356:1997;446-454.
245. Lu X.-Y., Ghasemzadeh M.B., Kalivas P.W. Regional distribution and cellular localization of γ-aminobutyric acid subtype 1 receptor mRNA in the rat brain. J. Comp. Neurol. 407:1999;166-182.
246. A receptor channels. Annu. Rev. Neurosci. 17:1994;569-602.
247. 2-adrenoceptor agonist has anxiolytic properties in rodents. FASEB J. 2:1988;7366.
248. 3) receptor antagonists. Pol. J. Pharmacol. Pharm. 44:1992;261-269.
249. 1B receptor knock-out mice exhibit increased exploratory activity and enhanced spatial memory performance in the Morris water maze. J. Neurosci. 19:1999;6157-6168.
250. Mansbach R.S., Harrod C., Hoffmann S.M., Nader M.A., Lei Z., Witkin J.M., Barrett J.E. Behavioral studies with anxiolytic drugs. V. Behavioral and in vivo neurochemical analyses in pigeons of drugs that increase punished responding. J. Pharmacol. Exp. Ther. 246:1988;114-120.
251. B receptors in the rat central nervous system. J. Comp. Neurol. 405:1999;299-321.
252. 2C receptor agonists: pharmacological characteristics and therapeutic potential. J. Pharmacol. Exp. Ther. 286:1998;913-924.
253. 2C receptor antagonist, SB-242084, in tests of anxiety. Pharmacol. Biochem. Behav. 71:2002;615-625.
254. Martin-Ruiz R., Puig V.M., Celada P., Shapiro D.A., Roth B.L., Mengod G., Artigas F. Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J. Neurosci. 21:2001;9856-9866.
255. Mason P., Skinner J., Luttinger D. Two tests in rats for antianxiety effect of clinically anxiety-attenuating antidepressants. Psychopharmacology. 92:1987;30-34.
256. Matheus M.G., Guimarães F.S. Antagonism of non-NMDA receptors in the periaqueductal grey induces anxiolytic effect in the elevated plus maze. Psychopharmacology. 132:1997;14-18.
257. Matsuo M., Kataoka Y., Mataki S., Kato Y., Oi K. Conflict situation increases serotonin release in rat dorsal hippocampus: in vivo study with microdialysis and Vogel test. Neurosci. Lett. 215:1996;197-200.
258. Matsuo M., Ayuse T., Oi K., Kataoka Y. Propofol produces anticonflict action by inhibiting 5-HT release in rat dorsal hippocampus. NeuroReport. 8:1997;3087-3090.
259. 1A receptors in guinea pig dentate gyrus. Brain Res. 761:1997;105-112.
260. McCullough L.D., Salamone J.D. Anxiogenic drugs beta-CCE and FG 7142 increase extracellular dopamine levels in nucleus accumbens. Psychopharmacology. 109:1992;379-382.
261. 1 subtype. Nat. Neurosci. 3:2000;587-592.
262. McQuade R., Creton D., Stanford S.C. Effect of novel environmental stimuli on rat behaviour and central noradrenaline function measured by in vivo microdialysis. Psychopharmacology. 145:1999;393-400.
263. Menard J., Treit D. The septum and the hippocampus differentially mediate anxiolytic effects of R(+)-8-OH-DPAT. Behav. Pharmacol. 9:1998;93-101.
264. Menard J., Treit D. Effects of centrally administered anxiolytic compounds in animal models of anxiety. Neurosci. Biobehav. Rev. 23:1999;591-613.
265. Menard J., Treit D. Intra-septal infusions of excitatory amino acid receptor antagonists have differential effects in two animal models of anxiety. Behav. Pharmacol. 11:2000;99-108.
266. Merchenthaler I., Lane M., Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J. Comp. Neurol. 403:1999;261-280.
267. Mihalek R.M., Banerjee P.K., Korpi E.R., Quinlan J.J., Firestone L.L., Mi Z.P.et al. Attenuated sensitivity to neuroactive steroids in α-aminobutyrate type A receptor delta subunit knockout mice. Proc. Natl. Acad. Sci. U. S. A. 96:1999;12905-12910.
268. Millan M.J. The induction of pain: an integrative review. Progr. Neurobiol. 57:1999;1-164.
269. Millan M.J. Descending control of pain. Progr. Neurobiol. 66:2002;355-474.
270. B receptors in the pathogenesis and treatment of schizophrenia: a critical review. Curr. Drug Targets - CNS Neurol. Disord. 1:2002;91-213.
271. 1C/2 antagonists. Drugs News Persp. 5:1992;397-406.
272. 1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties. J. Pharmacol. Exp. Ther. 282:1997;148-161.
273. 1A) agonist properties: III. Anxiolytic actions in comparison to clozapine and haloperidol. J. Pharmacol. Exp. Ther. 288:1999;1002-1014.
274. 2-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine. J. Pharmacol. Exp. Ther. 295:2000;1192-1205.
275. 2-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine. J. Pharmacol. Exp. Ther. 295:2000;1206-1222.
276. 3 receptors: significance for the modulation of frontocortical monoaminergic transmission and depressive states. Synapse. 35:2000;79-95.
277. Millan M.J., Lejeune F., Gobert A. Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J. Psychopharmacol. 14:2000;114-138.
278. 1 antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent. Neuropsychopharmacology. 25:2001;585-600.
279. s receptor subunit in the rat central nervous system. Eur. J. Neurosci. 15:2002;449-457.
280. Mizoule J., Gauthier A., Uzan A., Renault C., Dubroeucq M.C., Guérémy C., Le Fur G. Opposite effects of two ligands for peripheral type benzodiazepine binding sites, PK 11195 and RO5-4864, in a conflict situation. Life Sci. 36:1985;1059-1068.
281. Mizuki Y., Suetsugi M., Ushijima I., Yamada M. Differential aspects of dopaminergic drugs on anxiety and arousal in healthy volunteers with high and low anxiety. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 21:1997;573-590.
282. Moghaddam B. Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. Biol. Psychiatry. 51:2002;775-787.
283. (A) receptor subtypes: a new pharmacology. Curr. Opin. Pharmacol. 1:2001;22-25.
284. Möhler H., Fritschy J.M., Rudolph U. A new benzodiazepine pharmacology. J. Pharmacol. Exp. Ther. 300:2002;2-8.
285. Molchanov M.L., Guimarães F.S. Anxiolytic-like effects of AP7 injected into the dorsolateral or ventrolateral columns of the periaqueductal gray of rats. Psychopharmacology. 160:2002;30-38.
286. Möller C., Sommer W., Thorsell A., Heilig M. Anxiogenic-like action of galanin after intra-amygdala administration in the rat. Neuropsychopharmacology. 21:1999;507-512.
287. Möller C., Sommer W., Thorsell A., Rimondini R., Heilig M. Anxiogenic-like action of centrally administered glucagon-like peptide-1 in a punished drinking test. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 26:2002;119-122.
288. 2C receptor subtypes in the two types of fear generated by the elevated T-maze. Pharmacol. Biochem. Behav. 58:1997;1051-1057.
289. 3 receptor is present in different subpopulation of GABAergic neurons in the rat telencephalon. J. Neurosci. 17:1997;3157-3167.
290. 1B/D receptors in psychiatric disorders and their potential as a target for therapy. Eur. J. Pharmacol. 404:2000;1-12.
291. Morrow B.A., Elsworth J.D., Lee E.J.K., Roth R.H. Divergent effects of putative anxiolytics on stress-induced Fos expression in the mesoprefrontal system of the rat. Synapse. 36:2000;143-154.
292. 1A receptors on the exploratory activity of rats in the elevated plus-maze. Psychopharmacology. 107:1992;135-139.
293. Munro L.J., Kokkinidis L. Infusion of quinpirole and muscimol into the ventral tegmental area inhibits fear-potentiated startle: implications for the role of dopamine in fear expression. Brain Res. 746:1997;231-238.
294. Murugaiah K.D., O'Donnell J.M. Beta adrenergic receptors facilitate norepinephrine release from rat hypothalamic and hippocampal slices. Res. Commun. Mol. Pathol. Pharmacol. 90:1995;179-190.
295. Nazar M., Siemiatkowski M., Czlonkowska A., Sienkiewicz-Jarosz H., Plaźnik A. The role of hippocampus and 5-HT/GABA interaction in the central effects of benzodiazepine receptor ligands. J. Neural Transm. 106:1999;369-381.
296. Nicholas A.P., Hökfelt T., Pieribone V.A. The distribution and significance of CNS adrenoceptors examined with in situ hybridization. Trends Pharmacol. Sci. 18:1996;210-211.
297. Nikolaus S., Huston J.P., Hasenöhrl R.U. Anxiolytic-like effects in rats produced by ventral pallidal injection of both N- and C-terminal fragments of substance P. Neurosci. Lett. 283:2000;37-40.
298. Noble F., Roques B.P. CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology. Prog. Neurobiol. 58:1999;349-379.
299. Nogueira R.L., Graeff F.G. Role of 5-HT receptor subtypes in the modulation of dorsal periaqueductal gray generated aversion. Pharmacol. Biochem. Behav. 52:1995;1-6.
300. 2-adrenoceptors in specific brain regions of the rat. Brain Res. 401:1987;30-33.
301. Nunes-de-Souza R., Canto-de-Souza A., Rodgers R.J. Effects of intra-hippocampal infusion of WAY-100635 on plus-maze behavior in mice: influence of site of injection and prior test experience. Brain Res. 927:2002;87-96.
302. 3 receptor antagonists and anxiety: a preclinical and clinical review. Eur. Neuro-Psychopharmacol. 10:2000;77-95.
303. 1A receptor knockout mouse and anxiety. Behav. Pharmacol. 12:2001;439-450.
304. 1A-agonist tandospirone before otolaryngologic surgery. 93, 1214-1216.
305. Ozawa S., Kamiya H., Tzuzuki K. Glutamate receptors in the mammalian central nervous system. Prog. Neurobiol. 54:1998;581-618.
306. Palmiter R.D., Erickson J.C., Hollopeter G., Baraban S.C., Schwartz M.W. Life without neuropeptide Y. Recent Prog. Horm. Res. 53:1998;163-199.
307. 1A receptor knockout mice on a 129/Sv background. Eur. J. Pharmacol. 447:2002;67-74.
308. Pecknold J.C. A risk-benefit assessment of buspirone in the treatment of anxiety disorders. Drug Safety. 16:1997;118-132.
309. Penn D.L., Hope D.A., Spaulding W., Kucera J. Social anxiety in schizophrenia. Schizophr. Res. 11:1994;277-284.
310. Pezze M.A., Heidbreder C.A., Feldon J., Murphy C.A. Selective responding of nucleus accumbens core and shell dopamine to aversively conditioned contextual and discrete stimuli. Neuroscience. 108:2001;91-102.
311. Pich E.M., Samanin R. Disinhibitory effects of buspirone and low doses of sulpiride and haloperidol in two experimental anxiety models in rats: possible role of dopamine. Psychopharmacology. 89:1986;125-130.
312. 3 receptor antagonists BRL43694 and GR38032F in animal behavioural models of anxiety. Br. J. Pharmacol. 94:1988;. (314P).
313. A receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience. 101:2000;815-850.
314. Pitchot W., Ansseau M., Gonzalez Moreno A., Hansenne M., Von Frenckell R. Dopaminergic function in panic disorder: comparison with major and minor depression. Biol. Psychiatry. 32:1992;1004-1011.
315. Plaznik A., Jessa M., Bidzinski A., Nazar M. The effect of serotonin depletion and intra-hippocampal midazolam on rat behavior in the Vogel conflict test. Eur. J. Pharmacol. 257:1994;293-296.
316. Plaznik A., Nazar M., Jessa M. The limbic location of some central effects of competitive and noncompetitive NMDA receptor antagonists: the role in emotional control. Eur. Neuropsychopharmacol. 4:1994;335.
317. Plaznik A., Palejko W., Nazar M., Jessa M. Effects of antagonists at the NMDA receptor complex in two models of anxiety. Eur. Neuropsychopharmacol. 4:1994;503-512.
318. Pollard G.T., Howard J.C.L. Effects of drugs on punished behaviour: preclinical test for anxiolytics. Pharmacol. Ther. 45:1989;403-424.
319. Pribilla I., Neuhaus R., Huba R., Hillmann M., Turner J.D., Stephens
320. 1A receptors is responsible for the anticonflict effect of ipsapirone in rats. J. Pharm. Pharmacol. 44:1992;780-782.
321. 1A) receptors in the anticonflict activity of β-adrenoceptor antagonists. Pharmacol. Biochem. Behav. 47:1994;873-878.
322. 1A receptors in the anticonflict effect of ipsapirone. Neuropharmacology. 33:1994;1109-1115.
323. 1A) receptors in the anticonflict activity of β-adrenoceptor antagonists. Neuropharmacology. 34:1995;1211-1217.
324. Przegaliński E., Tatarczyńska E., Dereń-Wesolek L., Chojnacka-Wójcik E. Anticonflict effect of a competitive NMDA receptor antagonist and a partial agonist at strychnine-insensitive glycine receptors. Pharmacol. Biochem. Behav. 54:1996;73-77.
325. Przegaliński E., Tatarczyńska E., Klodzińska A., Chojnacka-Wójcik E. Tolerance to anxiolytic- and antidepressant-like effects of a partial agonist of glycineB receptors. Pharmacol. Biochem. Behav. 64:1999;461-466.
326. Przegaliński E., Tatarczyńska E., Chojnacka-Wójcik E. The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats. Neuropharmacology. 39:2000;1858-1864.
327. Purdy R.H., Morrow A.L., Moore P.H., Paul S.M. Stress-induced, elevations of γ-aminobutyric acid type A receptor-active steroids in the rat brain. Proc. Natl. Acad. Sci. U. S. A. 88:1991;4553-4557.
328. 1B receptor knock out-behavioral consequences. Behav. Brain Res. 73:1996;305-312.
329. Rasmussen K., Kendrick W.T., Kogan J.H., Aghajanian G.K. A selective AMPA antagonist, LY293558, antagonizes morphine-withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. Neuropsychopharmacology. 15:1996;497-505.
330. Ravard S., Carnoy P., Hervé D., Tassin J.P., Thiénot M.H., Soubrié P. Involvement of prefrontal dopamine neurones in behavioural blockade induced by controllable vs. uncontrollable negative events in rats. Behav. Brain. Res. 37:1990;9-18.
331. 2-adrenoceptors in the anxiogenic effects of yohimbine, using the selective antagonist, delequamine, in the rat. Br. J. Pharmacol. 116:1995;2081-2089.
332. Rickels K., Schweizer E., DeMartinis N., Mandos L., Mercer C. Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial. J. Clin. Psychopharmacol. 17:1997;272-277.
333. Rogers D.C., Costall B., Domeney A.M., Gerrard P.A., Greener M., Kelly M.E., Hagan J.J., Hunter A.J. Anxiolytic profile of ropinirole in the rat, mouse and common marmoset. Psychopharmacology. 151:2000;91-97.
334. Rodgers R.J. Animal models of "anxiety": where next? Behav. Pharmacol. 8:1997;477-796.
335. 2 receptor ligands modulate the behaviour of mice in the elevated plus-maze. Pharmacol. Biochem. Behav. 49:1994;985-995.
336. Rodgers R.J., Cao B.-J., Dalvi A., Holmes A. Animal models of anxiety: an ethological perspective. Braz. J. Med. Biol. Res. 30:1997;289-304.
337. 3 antagonist U-99194A maleate increases social behaviors of isolation-induced aggressive male mice. Psychopharmacology. 144:1999;90-94.
338. 3 receptor antagonist, in rats. Eur. Neuropsychopharmacol. 10:2000;S349.
339. Roozendaal B., Nguyen B.T., Power A.E., McGaugh J.L. Basolateral amygdala noradrenergic influence enables enhancement of memory consolidation induced by hippocampal glucocorticoid receptor activation. Proc. Natl. Acad. Sci. U. S. A. 96:1999;11642-11647.
340. Ropert N., Guy N. Serotonin facilitates GABAergic transmission in the CA1 region of rat hippocampus in vitro. J. Physiol. 441:1991;121-136.
341. Roy-Byrne P.P., Uhde T.W., Sack D.A., Linnoila M., Post R.M. Plasma HVA and anxiety in patients with panic disorder. Biol. Psychiatry. 21:1986;849-853.
342. A receptor subtypes. Nature. 401:1999;796-800.
343. Rueter L.E., Fornal C.A., Jacobs B.L. A critical review of 5-HT brain microdialysis and behavior. Rev. Neurosci. 8:1997;117-137.
344. Sajdyk T.J., Shekhar A. Excitatory amino acid receptors in the basolateral amygdala regulate anxiety responses in the social interaction test. Brain Res. 764:1997;262-264.
345. 1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. Eur. J. Pharmacol. 368:1999;143-147.
346. 2 receptors mediate anxiety in the amygdala. Pharmacol. Biochem. Behav. 71:2002;419-423.
347. 2C-receptors modulate the acoustic startle reflex, prepulse inhibition, and aggression in mice. J. Neurosci. 18:1998;3035-3042.
348. 2-adrenoceptor subtype C in mice affects the development of behavioral despair and stress-induced increases in plasma corticosterone levels. Mol. Psychiatry. 4:1999;443-452.
349. Schefke D.M., Fontana D.J., Commissaris R.L. Anti-conflict efficacy of buspirone following acute versus chronic treatment. Psychopharmacology. 99:1989;427-429.
350. Schmitt M.L., Coelho W., Lopes-de-Souza A.S., Guimarães F.S., Carobrez A.P. Anxiogenic-like effect of glycine and D-serine microinjected into dorsal periaqueductal gray matter of rats. Neurosci. Lett. 189:1995;93-96.
351. 2-adrenoceptor antagonist ethoxyidazoxan given to healthy volunteers. Psychopharmacology. 146:1999;119-127.
352. 2 receptor binding potential in social phobia. Am. J. Psychiatry. 157:2000;457-459.
353. Schoepp D.D., Jane D.E., Monn J.A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology. 38:1999;1431-1476.
354. 2A-adrenergic receptor plays a protective role in mouse behavioural models of depression and anxiety. J. Neurosci. 21:2001;4875-4882.
355. 1A receptor ligands in animal models of anxiety, impulsivity and depression: multiple mechanisms of action? Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 17:1993;87-104.
356. B(1). Neuron. 31:2001;47-58.
357. Schulz B., Fendt M., Schnitzler H.-U. Clonidine injections into the lateral nucleus of the amygdala block acquisition and expression of fear-potentiated startle. Eur. J. Neurosci. 15:2002;151-157.
358. Schwendt M., Jezová D. Gene expression of two glutamate receptor subunits in response to repeated stress exposure in rat hippocampus. Cell. Mol. Neurobiol. 20:2000;319-329.
359. Segieth J., Pearce B., Fowler L., Whitton P.S. Regulatory role of nitric oxide over hippocampal 5-HT release in vivo. Naunyn-Schmiedeberg's Arch. Pharmacol. 363:2001;302-306.
360. 1b Receptor antagonist. J. Pharmacol. Exp. Ther. 300:2002;1122-1130.
361. Setem J., Pinheiro A.P., Motta V.A., Morato S., Cruz A.P.M. Ethopharmacological analysis of 5-HT ligands on the rat elevated plus-maze. Pharmacol. Biochem. Behav. 62:1999;515-521.
362. 3 dopamine receptor in cellular and organismal functions. Psychopharmacology. 135:1998;1-16.
363. Sharma A.C., Kulkarni S.K. Evidence for benzodiazepine receptor interaction with MK 801 in anxiety related behaviour in rats. Indian J. Exp. Biol. 31:1993;191-193.
364. Shekhar A., McCann U.D., Meaney M.J., Blanchard D.C., Davis M., Frey K.A., Liberzon I., Overall K.L., Shear M.K., Tecott L.H., Winsky L. Summary of a National Institute of Mental Health workshop: developing animal models of anxiety disorders. Psychopharmacology. 157:2001;327-339.
365. Shekhar A., Katner J.S., Sajdyk T.J., Kohl R.R. Role of norepinephrine in the dorsomedial hypothalamic panic response: an in vivo microdialysis study. Pharmacol. Biochem. Behav. 71:2002;493-500.
366. 2 receptor facilitates GABAergic neurotransmission in rat hippocampus. J. Pharmacol. Exp. Ther. 285:1998;805-812.
367. Shephard R.A., Wedlock P., Wilson N.E. Direct evidence for the mediation of an anticonflict effect of baclofen by GABAb receptors. Pharmacol. Biochem. Behav. 41:1992;651-653.
368. Shiba M., Bower J.H., Maraganore D.M., McDonnell S.K., Peterson B.J., Ahlskog J.E., Schaid D.J., Rocca W.A. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov. Disord. Soc. 15:2000;669-677.
369. Shibata S., Yamashita K., Yamamoto E., Ozaki T., Ueki S. Effects of benzodiazepine and GABA antagonists on anticonflict effects of antianxiety drugs injected into the rat amygdala in a water-lick suppression test. Psychopharmacology. 98:1989;38-44.
370. Shimizu H., Hirose A., Tatsuno T., Nakamura M., Katsube J. Pharmacological properties of SM-3997: a new anxioselective anxiolytic candidate. Jpn J. Pharmacol. 45:1987;493-500.
371. Shimizu H., Tatsuno T., Tanaka H., Hirose A., Araki Y., Nakamura M. Serotonergic mechanisms in anxiolytic effect of tandospirone in the Vogel conflict test. Jpn. J. Pharmacol. 59:1992;105-112.
372. Shors T.J., Elkabes S., Selcher J.C., Black I.B. Stress persistently increases NMDA receptor-mediated binding of [3H] PDBu (a marker for protein kinase C) in the amygdala, and re-exposure to the stressful context reactivates the increase. Brain Res. 750:1997;293-300.
373. 1A receptors in mood disorders: a combined genetic and genomic approach. Behav. Pharmacol. 12:2001;429-438.
374. A receptor binding, and benzodiazepine-resistant anxiety. J. Neurosci. 20:2000;2758-2765.
375. Sibley D.R. New insights into dopaminergic receptor function using antisense and genetically altered animals. Annu. Rev. Pharmacol. Toxicol. 39:1999;313-341.
376. 2 receptor ligands on novelty-induced behavior in the rat open field test. Neurosci. Res. Comm. 27:2000;155-163.
377. Singewald N., Sharp T. Neuroanatomical targets of anxiogenic drugs in the hindbrain as revealed by Fos immunocytochemistry. Neuroscience. 98:2000;759-770.
378. B receptor antagonist. Br. J. Pharmacol. 104:1991;239-245.
379. Skolnick P., Miller R., Young A., Boje K., Trullas R. Chronic treatment with L-aminocyclopropanecarboxylic acid desensitizes behavioral responses to compounds acting at the N-methyl-D-aspartate receptor complex. Psychopharmacology. 107:1992;489-499.
380. Smith B.N., Dudek F.E. Amino acid-mediated regulation of spontaneous synaptic activity patterns in the rat basolateral amygdala. J. Neurophysiol. 76:1996;1958-1967.
381. Söderpalm B. The SHR exhibits less "anxiety" but increased sensitivity to the anticonflict effect of clonidine compared to normotensive controls. Pharmacol. Toxicol. 65:1989;381-386.
382. Söderpalm B., Engel J.A. Biphasic effects of clonidine on conflict behavior: involvement of different alpha-adrenoceptors. Pharmacol. Biochem. Behav. 30:1988;471-477.
383. 2-Adrenoceptor antagonists potentiate the anticonflict and the rotarod impairing effects of benzodiazepines. J. Neural Transm. 76:1989;191-204.
384. 1- and β-adrenoceptor stimulation potentiate the anticonflict effect of a benzodiazepine. J. Neural Transm. 79:1990;155-167.
385. A/benzodiazepine chloride ionophore receptor complex in the 5,7-DHT induced anticonflict effect. Life Sci. 49:1991;139-153.
386. Söderpalm B., Eriksson E., Engel J.A. Anticonflict and rotarod impairing effects of alprazolam and diazepam in rat after acute and subchronic administration. Prog. Neuro-Psychopharmacol. Biol. Psychiatr. 13:1989;269-283.
387. A/benzodiazepine chloride ionophore receptor complexes. Life Sci. 51:1992;327-335.
388. Söderpalm A., Blomqvist O., Söderpalm B. The yohimbine-induced anticonflict effect in the rat: Part I. Involvement of noradrenergic, serotonergic and endozepinergic(?) mechanisms. J. Neural Transm. 100:1995;175-189.
389. Söderpalm A., Ehrenström F., Söderpalm B. The yohimbine-induced anticonflict effect in the rat: Part II. Neurochemical findings. J. Neural Transm. 100:1995;191-206.
390. A/benzodiazepine receptor complexes. Neuropharmacology. 36:1997;1071-1077.
391. Sorbera L.A., Leeson P.A., Silvestre J., Castaner J. Pagoclone. Drugs Future. 26:2001;651-657.
392. Spooren W.P.J.M., Vassout A., Neijt H.C., Kuhn R., Gasparini F., Roux S., Porsolt R.D., Gentsch C. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J. Pharmacol. Exp. Ther. 295:2000;1267-1275.
393. 1A receptor agonists, partial agonists and a silent antagonist on the performance of the conditioned emotional response test in the rat. Psychopharmacology. 128:1996;293-303.
394. Steckler T., Holsboer F. Corticotropin-releasing hormone receptor subtypes and emotion. Biol. Psychiatry. 46:1999;1480-1508.
395. Stefański R., Palejko W., Kostowski W., Plaźnik A. The comparison of benzodiazepine derivatives and serotonergic agonists and antagonists in two animal models of anxiety. Neuropharmacology. 31:1992;1251-1258.
396. 1A receptor agonists. Neuropharmacology. 32:1993;977-985.
397. 3 receptor antagonists. Neuropharmacology. 32:1993;987-993.
398. Stein M.B., Sareen J., Hami S., Chao J. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am. J. Psychiatry. 158:2001;1725-1727.
399. 3 dopamine receptor-deficient mouse: evidence for reduced anxiety. Physiol Behav. 63:1998;137-141.
400. A conductances in hippocampal neurons. J. Neurosci. 22:2002;1-5.
401. Stephens D.N., Schneider H.H., Kehr W., Andrews J.S., Rettig K.-J., Turski L., Schmiechen R., Turner J.D., Jensen L.H., Petersern E.N., Honore T., Hansen B.J. Abecarnil, a metabolically stable, anxioselective β-carboline acting at benzodiazepine receptors. J. Pharmacol. Exp. Ther. 253:1990;334-343.
402. A receptor-modulating neuroactive steroid composition in patients with panic disorder before and during paroxetine treatment. Am. J. Psychiatry. 159:2002;145-147.
403. Sullivan G.M., Coplan J.D., Kent J.M., Gorman J.M. The noradrenergic system in pathological anxiety: a focus on panic with relevance to generalized anxiety and phobias. Biol. Psychiatry. 46:1999;1205-1218.
404. Suzuki T., Ishigooka J., Watanabe S., Miyaoka H. Enhancement of delayed release of dopamine in the amygdala induced by conditioned fear stress in methamphetamine-sensitized rats. Eur. J. Pharmacol. 435:2002;59-65.
405. Szabo C. Physiological and pathophysiological roles of nitric oxide in the central nervous system. Brain Res. Bull. 41:1996;131-141.
406. Tanaka M., Yoshida H., Emoto H., Ishii H. Noradrenaline systems in the hypothalamus, amygdala and locus coeruleus are involved in the provocation of anxiety: basic studies. Eur. J. Pharmacol. 405:2000;397-406.
407. A receptor subunit gene expression. Mol. Psychiatry. 6:2001;404-412.
408. Tanganelli S., Fuxe K., Antonelli T., O'Connor W.T., Ferraro L. Cholecystokinin/dopamine/GABA interaction in the nucleus accumbens: biochemical and functional correlates. Peptides. 22:2001;1229-1234.
409. B receptors in midbrain raphe nuclei and forebrain of rats. Br. J. Pharmacol. 119:1996;1375-1384.
410. Tatarczyńska E., Klodzińska A., Kroczka B., Chojnacka-Wójcik E., Pilc A. The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration. Psychopharmacology. 158:2001;94-99.
411. 11C]WAY-100635 PET investigation in healthy volunteers. Am. J. Psychiatry. 158:2001;1326-1328.
412. Teixeira K.V., Carobrez A.P. Effects of glycine or (±)-3-amino-1-hydroxy-2-pyrrolidone microinjections along the rostrocaudal axis of the dorsal periaqueductal gray matter on rats performance in the elevated plus-maze task. Behav. Neurosci. 113:1999;196-203.
413. Tejani-Butt S.M., Pare W.P., Yang J. Effect of repeated novel stressors on depressive behavior and brain norepinephrine receptor system in Sprague-Dawley and Wistar Kyoto (WKY) rats. Brain Res. 649:1994;27-35.
414. Thomson I.R., Peterson M.D., Hudson R.J. A comparison of clonidine with conventional pre-anesthetic medication in patients undergoing coronary artery bypass grafting. Anesth. Analg. 87:1998;292-299.
415. Thorsell A., Michalkiewicz M., Dumont Y., Quirion R., Caberlotto L., Rimondini R., Mathé A.A., Heilig M. Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression. Proc. Natl. Acad. Sci. U. S. A. 97:2000;12852-12853.
416. Tiihonen J., Kuikka J., Bergström K., Lepola U., Koponen H., Leinonen E. Dopamine reuptake site densities in patients with social phobia. Am. J. Psychiatry. 154:1997;239-242.
417. Timothy C., Costall B., Smythe J.W. Effects of SCH23390 and raclopride on anxiety-like behaviour in rats tested in the black-white box. Pharmacol. Biochem. Behav. 62:1999;323-327.
418. Treit D. Animal models for the study of anti-anxiety agents: a review. Neurosci. Biobehav. Rev. 9:1985;203-222.
419. Treit D. Animal models of anxiety and anxiolytic drug action. den Boer J.A., Sutsen J.M.A. Handbook of Depression and Anxiety. 1994;201-224.
420. Tsuiki K., Blier P., Diksic M. Effect of the β-adrenoceptor agonist flerobuterol on serotonin synthesis in the rat brain. Biochem. Pharmacol. 59:2000;673-679.
421. Turski L., Jacobsen P., Honoré T., Syephens N. Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline. J. Pharmacol. Exp. Ther. 260:1992;742-747.
422. Tyrer P. Anxiolytics not acting at the benzodiazepine receptor: beta blockers. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 16:1992;17-26.
423. Ueki S., Watanabe S., Yamamoto T., Kataoka Y., Shibata S., Shibata K., Ohta H., Shimazoe T., Kawamoto H. Behavioral and electroencephalographic effects of zopiclone, a cyclopyrrolone derivative. Jpn. J. Pharmacol. 43:1987;309-326.
424. Umezu T. Effects of psychoactive drugs in the Vogel conflict test in mice. Jpn J. Pharmacol. 80:1999;111-118.
425. 1b and oxytocin receptor messenger ribonucleic acids in brain. Endocrinology. 139:1998;5015-5033.
426. Valentino R.J., Van Bockstaele E. Opposing regulation of the locus coeruleus by corticotropin-releasing factor and opioids. Psychopharmacology. 158:2001;331-342.
427. Vallone D., Picetti R., Borrelli E. Structure and function of dopamine receptors. Neurosci. Biobehav. Rev. 24:2000;125-132.
428. 3 receptor knock-out mice. Behav. Brain Res. 130:2002;141-148.
429. Van Gaalen M.M., Steckler T. Behavioural analysis of four mouse strains in an anxiety test battery. Behav. Res. 115:2000;95-106.
430. Vanover K.E., Robledo S., Huber M., Carter R.B. Pharmacological evaluation of a conflict procedure: punished drinking in non-water-deprived rats. Psychopharmacology. 145:1999;333-341.
431. A receptors. J. Pharmacol. Exp. Ther. 295:2000;337-345.
432. (B) receptors in the median raphe nucleus: distribution and role in the serotonergic control of hippocampal activity. Neurosci. 109:2002;119-132.
433. Venault P., Jacquot F., Save E., Sara S., Chapouthier G. Anxiogenic-like effects of yohimbine and idazoxan in two behavioural situations in mice. Life Sci. 52:1993;639-645.
434. Vogel J.R., Beer B., Clody D.E. A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia. 21:1971;1-7.
435. Wada T., Fukuda N. Effects of DN-2327, a new anxiolytic, diazepam and buspirone on exploratory activity of the rat in an elevated plus-maze. Psychopharmacology. 104:1991;444-450.
436. Waddington J.L., Clifford J.J., McNamara F.N., Tomiyama K., Koshikawa N., Croke D.T. The psychopharmacology-molecular biology interface: exploring the behavioural roles of dopamine receptor subtypes using targeted gene deletion ('knockout'). Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 25:2001;925-964.
437. B receptor antagonists with similar potency: no evidence for pharmacologically diferent presynaptic receptors. Br. J. Pharmacol. 113:1994;1515-1521.
438. Weiss S.M., Lightowler S., Stanhope K.J., Kennett G.A., Dourish C.T. Measurement of anxiety in transgenic mice. Rev. Neurosci. 11:2000;59-74.
439. Wieland S., Lan N.C., Mirasedeghi S., Gee K.W. Anxiolytic activity of the progesterone metabolite 5 alpha-pregnan-3-alpha-ol-20-one. Brain Res. 565:1991;263-268.
440. Wieland S., Belluzzi J., Hawkinson J.E., Hogenkamp D., Upasani R., Stein L., Wood P.L., Gee K.W., Lan N.C. Anxiolytic and anticonvulsant activity of a synthetic neuroactive steroid Co 3-0593. Psychopharmacology. 134:1997;46-54.
441. Wiesinger H. Arginine metabolism and the synthesis of nitric oxide in the nervous system. Prog. Neurobiol. 64:2001;365-391.
442. Wiley J.L., Porter J.H., Compton A.D., Balster R.L. Antipunishment effects of acute and repeated administration of phencyclidine and NPC 12626 in rats. Life Sci. 50:1992;1519-1528.
443. Wiley J.L., Compton A.D., Holcomb J.D., McCallum S.E., Varvel S.A., Porter J.H., Balster R.L. Effects of modulation of NMDA neurotransmission on response rate and duration in a conflict procedure in rats. Neuropharmacology. 37:1998;1527-1534.
444. Willetts J., Balster L., Leander J.D. The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol. Sci. 11:1990;423-428.
445. Willetts J., Clissold D.B., Hartman T.L., Brandsgaard R.R., Hamilton G.S., Ferkany J.W. Behavioral pharmacology of NPC 17742, a competitive N-methyl-D-aspartate (NMDA) antagonist. J. Pharmacol. Exp. Ther. 265:1993;1055-1062.
446. B receptors in midbrain monoamine containing neurons in the rat. Brain Res. Bull. 56:2001;1-5.
447. A receptor subunit mRNAs in the rat brain: I. Telencephalon, Diencephalon, Mesencephalon. J. Neurosci. 12:1992;1040-1062.
448. Wittchen H.U., Kessler R.C., Beesdo K., Krause P., Höfler M., Hoyer J. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J. Clin. Psychiatry. 8:2002;24-34.
449. Wood S.J., Toth M. Molecular pathways of anxiety revealed by knockout mice. Mol. Neurobiol. 23:2001;101-119.
450. 2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. Neuropharmacology. 41:2001;186-199.
451. 1A levels in the ventral hippocampus of rats during behaviour on the elevated X-maze. Psychopharmacology. 109:1992;338-346.
452. 2A) receptors in the rat brain. Brain Res. Bull. 51:2000;499-505.
453. Zangrossi H., Viana M.B., Graeff F.G. Anxiolytic effect of intra-amygdala injection of midazolam and 8-hydroxy-2-(di-n-propylamino)tetralin in the elevated T-maze. Eur. J. Pharmacol. 369:1999;267-270.
454. C receptors: a comparison of native versus recombinant receptors. Trends Pharmacol. Sci. 22:2001;121-132.
455. Zhang H.T., Frith S.A., Wilkins J., O'Donnell J.M. Comparison of the effects of isoproterenol administered into the hippocampus, frontal cortex or amygdala on behavior of rats maintained by differential reinforcement of low response rate. Psychopharmacology. 159:2001;89-97.
456. 1B receptors. Neuropsychopharmacology. 21:1999;52S-60S.
457. 1A-antagonist pindolol in patients with panic disorder. Biol. Psychiatry. 47:2000;81S.
458. Zinder O., Dar D.E. Neuroactive steroids: their mechanism of action and their function in the stress response. Acta Physiol. Scand. 167:1999;181-188.